乳腺癌复发早期检测的当前方法与挑战
Current approaches and challenges in early detection of breast cancer recurrence.
作者信息
Schneble Erika J, Graham Lindsey J, Shupe Matthew P, Flynt Frederick L, Banks Kevin P, Kirkpatrick Aaron D, Nissan Aviram, Henry Leonard, Stojadinovic Alexander, Shumway Nathan M, Avital Itzhak, Peoples George E, Setlik Robert F
机构信息
1. San Antonio Military Medical Center (SAMMC), 3551 Roger Brooke Dr., Ft. Sam Houston, TX 78234, USA.
2. Hadassah Medical Center, Kiryat Hadassah, POB 12000, Jerusalem, 91120, Israel.
出版信息
J Cancer. 2014 Mar 16;5(4):281-90. doi: 10.7150/jca.8016. eCollection 2014.
Abstract
Early detection of breast cancer recurrence is a key element of follow-up care and surveillance after completion of primary treatment. The goal is to improve survival by detecting and treating recurrent disease while potentially still curable assuming a more effective salvage surgery and treatment. In this review, we present the current guidelines for early detection of recurrent breast cancer in the adjuvant setting. Emphasis is placed on the multidisciplinary approach from surgery, medical oncology, and radiology with a discussion of the challenges faced within each setting.
摘要
乳腺癌复发的早期检测是初次治疗完成后随访护理和监测的关键要素。目标是通过在假定有更有效的挽救性手术和治疗的情况下，在疾病仍有可能治愈时检测并治疗复发性疾病来提高生存率。在本综述中，我们介绍了辅助治疗环境下复发性乳腺癌早期检测的当前指南。重点是手术、医学肿瘤学和放射学的多学科方法，并讨论了每种情况下面临的挑战。
相似文献
1
Current approaches and challenges in early detection of breast cancer recurrence.乳腺癌复发早期检测的当前方法与挑战
J Cancer. 2014 Mar 16;5(4):281-90. doi: 10.7150/jca.8016. eCollection 2014.
2
Future directions for the early detection of recurrent breast cancer.复发性乳腺癌早期检测的未来方向。
J Cancer. 2014 Mar 16;5(4):291-300. doi: 10.7150/jca.8017. eCollection 2014.
3
Current approaches and challenges in monitoring treatment responses in breast cancer.乳腺癌治疗反应监测的当前方法与挑战
J Cancer. 2014 Jan 5;5(1):58-68. doi: 10.7150/jca.7047.
4
Overview of resistance to systemic therapy in patients with breast cancer.乳腺癌患者全身治疗耐药概述。
Adv Exp Med Biol. 2007;608:1-22. doi: 10.1007/978-0-387-74039-3_1.
5
Gene expression profiling for guiding adjuvant chemotherapy decisions in women with early breast cancer: an evidence-based and economic analysis.用于指导早期乳腺癌女性辅助化疗决策的基因表达谱分析：基于证据的经济分析
Ont Health Technol Assess Ser. 2010;10(23):1-57. Epub 2010 Dec 1.
6
Evaluation of an intensive strategy for follow-up and surveillance of primary breast cancer.原发性乳腺癌随访与监测强化策略的评估
Ann Surg Oncol. 1998 Sep;5(6):522-8. doi: 10.1007/BF02303645.
7
Reducing the risk for breast cancer recurrence after completion of tamoxifen treatment in postmenopausal women.降低绝经后女性他莫昔芬治疗结束后乳腺癌复发风险。
Clin Ther. 2007 Aug;29(8):1535-47. doi: 10.1016/j.clinthera.2007.08.013.
8
9
ACR Appropriateness Criteria stage I breast cancer: initial workup and surveillance for local recurrence and distant metastases in asymptomatic women.ACR 适宜性标准Ⅰ期乳腺癌：无症状女性局部复发和远处转移的初始检查和监测。
J Am Coll Radiol. 2014 Dec;11(12 Pt A):1160-8. doi: 10.1016/j.jacr.2014.08.020. Epub 2014 Oct 23.
10
ACR Appropriateness Criteria Stage I Breast Cancer: Initial Workup and Surveillance for Local Recurrence and Distant Metastases in Asymptomatic Women.美国放射学会（ACR）适宜性标准：I期乳腺癌——无症状女性局部复发及远处转移的初始检查与监测
J Am Coll Radiol. 2016 Nov;13(11S):e43-e52. doi: 10.1016/j.jacr.2016.09.023.
引用本文的文献
1
Current trends in breast cancer genetics, risk factors, and screening strategies.乳腺癌遗传学、风险因素及筛查策略的当前趋势
J Biol Methods. 2025 Mar 13;12(2):e99010054. doi: 10.14440/jbm.2025.0079. eCollection 2025.
2
Monitoring breast cancer progression through circulating methylated GCM2 and TMEM240 detection.通过检测循环中的甲基化GCM2和TMEM240监测乳腺癌进展。
Clin Epigenetics. 2025 Jul 21;17(1):128. doi: 10.1186/s13148-025-01939-4.
3
Hepatic and extra-hepatic hydatid cysts: A case series of radiological and clinical insights.肝内和肝外包虫囊肿：放射学与临床见解的病例系列
Radiol Case Rep. 2025 Mar 20;20(6):2836-2844. doi: 10.1016/j.radcr.2025.02.040. eCollection 2025 Jun.
4
Rapid sorting and auxiliary evaluation of malignant breast tumors by accurate imaging analysis of metastasis-related biomarker.通过转移相关生物标志物的精确成像分析对乳腺恶性肿瘤进行快速分类和辅助评估
Sci Adv. 2025 Apr 4;11(14):eadr5541. doi: 10.1126/sciadv.adr5541. Epub 2025 Apr 2.
5
Circulating methylated tumor DNA as a biomarker for mortality in recurrent breast cancer: An exploratory study.循环甲基化肿瘤DNA作为复发性乳腺癌死亡率的生物标志物：一项探索性研究。
Oncol Lett. 2024 Oct 2;28(6):581. doi: 10.3892/ol.2024.14714. eCollection 2024 Dec.
6
Differentiating Primary and Recurrent Lesions in Patients with a History of Breast Cancer: A Comprehensive Review.乳腺癌病史患者原发性和复发性病变的鉴别：一项综述。
Galen Med J. 2024 Apr 22;13:e3340. doi: 10.31661/gmj.v13i.3340. eCollection 2024.
7
Therapeutic Peptide RF16 Derived from CXCL8 Inhibits MDA-MB-231 Cell Invasion and Metastasis.来源于 CXCL8 的治疗性肽 RF16 抑制 MDA-MB-231 细胞侵袭和转移。
Int J Mol Sci. 2023 Sep 13;24(18):14029. doi: 10.3390/ijms241814029.
8
Homogeneous Adaboost Ensemble Machine Learning Algorithms with Reduced Entropy on Balanced Data.基于平衡数据上具有降低熵的同质自适应提升集成机器学习算法
Entropy (Basel). 2023 Jan 29;25(2):245. doi: 10.3390/e25020245.
9
Primary care provider-led cancer survivorship care in the first 5 years following initial cancer treatment: a scoping review of the barriers and solutions to implementation.初级保健提供者主导的癌症生存护理在初始癌症治疗后的头 5 年内：实施障碍和解决方案的范围综述。
J Cancer Surviv. 2024 Apr;18(2):352-365. doi: 10.1007/s11764-022-01268-y. Epub 2022 Nov 15.
10
Pharmacometabolomics reveals urinary diacetylspermine as a biomarker of doxorubicin effectiveness in triple negative breast cancer.药物代谢组学揭示尿二乙酰精胺作为三阴性乳腺癌中多柔比星疗效的生物标志物。
NPJ Precis Oncol. 2022 Oct 7;6(1):70. doi: 10.1038/s41698-022-00313-4.
本文引用的文献
1
Screening MR imaging versus screening ultrasound: pros and cons.
Magn Reson Imaging Clin N Am. 2013 Aug;21(3):495-508. doi: 10.1016/j.mric.2013.04.001. Epub 2013 Jun 3.
2
Prognosis following local recurrence after breast conserving treatment in young women with early breast cancer.早期乳腺癌保乳治疗后局部复发患者的预后。
Eur J Surg Oncol. 2013 Aug;39(8):892-8. doi: 10.1016/j.ejso.2013.05.004. Epub 2013 May 30.
3
Imaging breast cancer bone metastases: current status and future directions.乳腺癌骨转移的影像学诊断：现状与未来方向。
Semin Nucl Med. 2013 Jul;43(4):317-23. doi: 10.1053/j.semnuclmed.2013.02.002.
4
Serum HER-2: sensitivity, specificity, and predictive values for detecting metastatic recurrence in breast cancer patients.血清 HER-2：用于检测乳腺癌患者转移复发的敏感性、特异性和预测值。
J Cancer Res Clin Oncol. 2013 Jun;139(6):1005-13. doi: 10.1007/s00432-013-1411-7. Epub 2013 Mar 13.
5
Pilot prospective evaluation of 99mTc-MDP scintigraphy, 18F NaF PET/CT, 18F FDG PET/CT and whole-body MRI for detection of skeletal metastases.前瞻性评估 99mTc-MDP 闪烁扫描、18F-NaF PET/CT、18F-FDG PET/CT 和全身 MRI 检测骨骼转移的初步研究。
Clin Nucl Med. 2013 Jul;38(7):e290-6. doi: 10.1097/RLU.0b013e3182815f64.
6
Sensitivity of CA 15-3, CEA and serum HER2 in the early detection of recurrence of breast cancer.CA 15-3、CEA 和血清 HER2 在乳腺癌早期复发检测中的敏感性。
Clin Chem Lab Med. 2013 Jul;51(7):1511-9. doi: 10.1515/cclm-2012-0488.
7
The role of 18F-fluoride PET-CT in the detection of bone metastases in patients with breast, lung and prostate carcinoma: a comparison with FDG PET/CT and 99mTc-MDP bone scan.18F-氟代脱氧葡萄糖正电子发射断层扫描/计算机断层扫描在检测乳腺癌、肺癌和前列腺癌患者骨转移中的作用：与氟代脱氧葡萄糖正电子发射断层扫描/计算机断层扫描和 99mTc-亚甲基二膦酸盐骨扫描的比较。
Jpn J Radiol. 2013 Apr;31(4):262-9. doi: 10.1007/s11604-013-0179-7. Epub 2013 Feb 2.
8
ACR Appropriateness Criteria Breast Cancer Screening.ACR 适宜性标准：乳腺癌筛查。
J Am Coll Radiol. 2013 Jan;10(1):11-4. doi: 10.1016/j.jacr.2012.09.036.
9
An evaluation of post-lumpectomy recurrence rates: is follow-up every 6 months for 2 years needed?评估保乳术后复发率：是否需要在 2 年内每 6 个月进行一次随访？
J Surg Oncol. 2013 May;107(6):597-601. doi: 10.1002/jso.23298. Epub 2012 Dec 27.
10
Breast cancer follow-up and management after primary treatment: American Society of Clinical Oncology clinical practice guideline update.原发性治疗后的乳腺癌随访和管理：美国临床肿瘤学会临床实践指南更新。
J Clin Oncol. 2013 Mar 1;31(7):961-5. doi: 10.1200/JCO.2012.45.9859. Epub 2012 Nov 5.
Zotero 插件